About Umoja Biopharma
Umoja Biopharma develops in vivo CAR T cell therapies for patients with cancer. The company's VivoVec platform generates CAR T cells directly in a patient's body. Umoja Biopharma manufactures its lentiviral products in-house.
Company Details
Corporate & Operational Profile
Web & Domain Identity
Social & Network Presence
Company Milestones & Timeline
- Capital Raise
Raised $100,000,000 · Series-B+
startupintros.com
- Capital Raise
Raised $210,000,000 · Series-B+
- Capital Raise
Raised $53,000,000 · Series-A
startupintros.com
- Milestone
X account created (@UmojaBiopharma)
318 followers
- Milestone
Website domain registered
umoja-biopharma.com
- Milestone
Company founded
Seattle, United States
Investors & Backers
Funding History
Founders & Leadership
Andrew Scharenberg
Founder
David Fontana
Chief Operating Officer
Philip Low
Founder
Ryan Crisman
Founder
Tim Gardner
Executive Vice President-Strategy and Business Development
Press Coverage & Sources
startupintros.com/news/2025-01-01-umoja-biopharma-series-c
fundraisingfox.com/companies/umoja-biopharma-inc
prnewswire.com/news-releases/umoja-biopharma-closes-an-oversubscribed-210-million-series-b-financing-to-expand-integrated-immunotherapy-platforms-and-advance-programs-to-the-clinic-301312026.html
startupintros.com/news/2020-11-01-umoja-biopharma-series-a
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Hexagon Bio
hexagonbio.com
RefloDx
reflodx.com
HeyVoli
heyvoli.com
CureBay
curebay.com
4Tissue
4tissue.com